scholarly journals Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients

2008 ◽  
Vol 101 (8) ◽  
pp. 1145-1149 ◽  
Author(s):  
An Pan ◽  
Wendy Demark-Wahnefried ◽  
Xingwang Ye ◽  
Zhijie Yu ◽  
Huaixing Li ◽  
...  
Keyword(s):  
Binding Protein ◽  
Retinol Binding Protein ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Retinol Binding Protein 4 ◽  
Reactive Protein ◽  
Type 2 Diabetics ◽  
Group 1

Elevated C-reactive protein (CRP), IL-6 and retinol-binding protein 4 (RBP4) levels are associated with insulin resistance and diabetes mellitus. Phytoestrogens (including lignans and isoflavones) may enhance the management of diabetes and are hypothesized to act through inflammation pathways. The present study explored the effects of flaxseed-derived lignan on inflammatory factors and RBP4 concentrations in type 2 diabetics, who have higher levels of these biomarkers. Seventy community-dwelling diabetic patients (twenty-six men and forty-four post-menopausal women) with mild hypercholesterolaemia completed a randomized, double-blind, placebo-controlled, cross-over trial of supplementation with flaxseed-derived lignan capsules (360 mg/d) or placebo for 12 weeks, separated by an 8-week wash-out period. The participants maintained their habitual diets and levels of physical activity. Baseline to follow-up concentrations of CRP increased significantly within the placebo group (1·42 (sem 0·19) v. 1·96 (sem 0·22) mg/l, P < 0·001), but were comparatively unchanged in the lignan-supplemented group (1·67 (sem 0·19) v. 1·90 (sem 0·26) mg/l, P = 0·94); a significant difference was observed between treatments ( − 0·45 (95 % CI − 0·76, − 0·08) mg/l, P = 0·021). This effect was confined to women (P = 0·016), but not observed in men (P = 0·49). No between-treatment differences were found with regard to IL-6 or RBP4; though IL-6 concentrations increased significantly from baseline to follow-up in both groups (P = 0·004 and P < 0·001 following lignan and placebo treatments, respectively). The study suggests that lignan might modulate CRP levels in type 2 diabetics. These results need to be confirmed by further large clinical trials of longer duration.

scholarly journals Evaluation of Ischemia-Modified Albumin and C-Reactive Protein in Type 2 Diabetics with and without Ketosis

2012 ◽  
Vol 7 ◽  
pp. BMI.S9060 ◽  
Author(s):  
Shao-gang Ma ◽  
Yao Jin ◽  
Wen Hu ◽  
Feng Bai ◽  
Wen Xu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Type 2 Diabetic Patients ◽  
Ischemia Modified Albumin ◽  
Protein Levels ◽  
Reactive Protein ◽  
Diabetic Ketosis ◽  
Type 2 Diabetics

Overview To investigate whether serum ischemia-modified albumin or C-reactive protein is reliable for predicting type 2 diabetic patients with ketosis. Approach One hundred and four diabetic patients, 48 with diabetic ketosis, and 33 controls were enrolled in the study. Serum ischemia-modified albumin and C-reactive protein were measured and evaluated for their ability to distinguish diabetic ketosis. Results Compared to the controls, the ischemia-modified albumin and C-reactive protein levels were higher in patients with diabetic ketosis and type 2 diabetes at the baseline. The levels of ischemia-modified albumin were higher in patients with type 2 diabetes than in the controls. C-reactive protein and ischemia-modified albumin levels were reduced after insulin treatment. The level of ischemia-modified albumin was an independent risk marker for diabetic ketosis ( OR = 1.085, P = 0.008, 95% CI: 1.022–1.152). Receiver operating characteristic curves revealed that the areas under the curve were 0.917 for the modified albumin and 0.357 for C-reactive protein. Conclusion This study indicates that ischemia-modified albumin was significantly associated with diabetic ketosis and was more sensitive than C-reactive protein in reflecting diabetic ketosis.

scholarly journals Role of Retinol-Binding Protein 4 in Obese Asian Indians with Metabolic Syndrome

2012 ◽  
Vol 31 (1) ◽  
pp. 40-46
Author(s):  
Nirupama Shivakumar ◽  
Meghanaa Kumar ◽  
Manasa Aswathanarayan ◽  
Maanasa Venkatesh ◽  
Manasa Sheshadri ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Asian Indians ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
C Reactive Protein ◽  
Retinol Binding Protein 4 ◽  
Reactive Protein ◽  
Potential Marker

Role of Retinol-Binding Protein 4 in Obese Asian Indians with Metabolic SyndromeRetinol-binding protein 4 is an adipocytokine separately implicated in the development of obesity-related insulin resistance and proatherogenic lipid profile, however, its role in humans is unclear. This study was carried out to assess the role of retinol-binding protein 4 as a potential marker of metabolic syndrome in obese Asian Indians (a high-risk population for diabetes). 52 obese (BMI >23 kg/m2) Asian Indians were grouped into those with and without metabolic syndrome based on IDF criteria and compared with healthy controls. The anthropometric and biochemical parameters (fasting blood sugar, lipid profile, serum insulin, high-sensitivity C-reactive protein, and retinol-binding protein 4) were estimated. The obese groups had significantly altered adiposity indices, insulin resistance parameters (fasting blood sugar (only in the metabolic syndrome group), serum insulin, HOMA-IR and QUICKI), index of inflammation (C-reactive protein) and proatherogenic dyslipidemic profile (serum triglycerides, VLDL-cholesterol, and triglyceride/HDL-cholesterol ratio). Retinol-binding protein 4 levels were elevated in the obese groups, but were not significant. Retinol-binding protein 4 levels were correlated with anthro-pometric parameters and atherogenic lipids, while C-reactive protein was correlated with anthropometric and insulin resistance parameters in the entire group of subjects. Although these correlations were not observed in the obese groups, in the control group, retinol-binding protein 4 was correlated to the lipid parameters and C-reactive protein to adiposity indices. Thus, the role of retinol-binding protein 4 as a potential marker of metabolic syndrome is limited to the prediction of proatherogenic risk among Asian Indians.

scholarly journals COVID-19 AMONG DIABETES PATIENTS TYPE 2

2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Mozoun Dafer Alahmari
Keyword(s):  
T Lymphocyte ◽  
Serum Amyloid A ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Amyloid A

A total of 74 COVID-19 diabetic patients were enrolled in the study. Twenty-seven patients (36.5%) were severely ill, and ten patients (13.5%) died. Severe patients had higher blood glucose, serum amyloid A (SAA), C reactive protein, and interleukin 6 levels than non-severe patients (P>  0.05). Severe patients had lower levels of albumin, cholesterol, high density lipoprotein, small and dense low density lipoprotein, and CD4 T lymphocyte counts than non-severe patients (P > 0.05). Reduced CD4 21 + T lymphocyte counts (OR = 0.988, 95 percent confidence interval [95 percent CI] 0.979–0.997) and elevated SAA levels (OR = 1.029, 95 percent CI 1.002–1.058) were found as risk variables for COVID- 19 severity with diabetes in a logistic regression analysis (P > 0.05). Keywords: COVID-19, Diabetes, Hyperglycemia, Dislipidemia, CD4+ T lymphocyte , follow up symptoms.

scholarly journals Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy

2016 ◽  
Vol 11 ◽  
pp. BMI.S33191 ◽  
Author(s):  
Mohamed H. Mahfouz ◽  
Adel M. Assiri ◽  
Mohammed H. Mukhtar
Keyword(s):  
Early Detection ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Retinol Binding Protein 4 ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase ◽  
Type 2 Diabetic

Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes. The study aims to evaluate the diagnostic value of serum neutrophil gelatinase-associated lipocalin (NGAL) and retinol-binding protein 4 (RBP4) as biomarkers for early detection of nephropathy in type 2 diabetic patients. The current study was performed on 150 type 2 diabetic patients. These patients were classified into three equal groups according to their albumin/creatinine ratio (ACR), including patients with normoalbuminuria (ACR <30 mg/g creatinine), patients with microalbuminuria (ACR = 30–300 mg/g creatinine), and patients with macroalbuminuria (ACR >300 mg/g creatinine). Fifty apparently healthy subjects matching the same age and socioeconomic status with diabetic subjects were selected as a control group. The plasma glucose, insulin, glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), lipid profile, urea, creatinine, cystatin C, glomerular filtration rate (GFR), NGAL, and RBP4 were measured in the studied groups. Significantly elevated NGAL and RBP4 levels were observed in micro- and macroalbuminuric diabetic groups when compared to the control and normoalbuminuric diabetic groups. NGAL and RBP4 were found to correlate positively with duration of diabetes, systolic and diastolic blood pressure, glucose, HbA1c, HOMA-IR, triacylglycerol, and ACR, but correlate inversely with GFR in DN groups. Receiver operating characteristic curves revealed that for early detection of DN, the best cutoff values to discriminate DN and diabetic without nephropathy groups were 91.5 ng/mL for NGAL with 87% sensitivity, 74% specificity, and area under the curve (AUC) = 0.881; 24.5 ng/mL for RBP4 with 84% sensitivity, 90% specificity, and AUC = 0.912; and 37.5 mg/g creatinine for ACR with 89% sensitivity, 72% specificity, and AUC = 0.819. RBP4 is more specific (90% specificity) than NGAL (74% specificity) and ACR (72% specificity). Therefore, RBP4 marker may serve as a tool to follow-up clinical monitoring of the development and progression of DN.

Sign in / Sign up

Export Citation Format

Share Document